Long-term Follow-up Study of BRL-101 for TDT

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age3-35

SponsorBioray Laboratories

About this trial

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)

Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.

None

45 Participants

are divided into 1 treatment group

Bioray Laboratories

Lead sponsor

First Affiliated Hospital of Guangxi Medical University

Collaborator

Xiangya Hospital of Central South University

Collaborator

Chinese Academy of Medical Sciences

Collaborator

Nanfang Hospital, Southern Medical University

Collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborator

The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

Collaborator

Shenzhen Children 's Hospital

Collaborator